A growing unregulated market in the U.S. is selling stem cell treatments marketed as a way to extend life and improve health, despite warnings from medical experts that such claims lack scientific backing and pose serious risks. Investigative reporting reveals how clinics are capitalizing on consumer demand for unproven therapies, offering procedures that promise dramatic benefits without sufficient evidence of safety or effectiveness. Critics emphasize that these treatments could lead patients to delay or avoid proven medical care while exposing them to potential harm. The findings raise concerns about the need for stronger oversight in an industry where hope often outweighs caution.
An FT investigation has found a thriving market for stem cell therapies in the US promising longer, healthier lives. Experts say such claims are dangerous
